Strategic Acquisition Foresight Diagnostics was acquired by Natera in December 2025 for a substantial upfront and milestone-based earn-out, signaling a strong validation of their CLARITY MRD platform and potential for broader integration within Natera's oncology portfolio.

Expanded Channel Post-acquisition, opportunities may exist to leverage Natera's established distributor and customer networks to scale adoption of CLARITY MRD, especially in larger clinical labs and hospital systems seeking proven ctDNA assays.

Clinical Validation Ongoing and upcoming presentations and trials, including PRECISE-HL and IASLC 2025 data, provide talking points for joint marketing, payer discussions, and expansion into hematologic malignancies and solid tumor MRD applications.

Kit Collaboration Partnering with Qiagen on a kit-based CLARITY NGS assay creates a pathway to lower adoption barriers, streamline workflows, and reach labs prioritizing turnkey solutions and standardized integrations.

Laboratory Footprint With a CLIA-certified Boulder lab and a mid-sized employee base, there is near-term potential to offer managed testing services, CRO-style collaborations, and contract development/manufacturing opportunities to biotech and academic partners.